Abstract: The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.

Abstract: The invention relates to a novel process for the preparation of (3S,4S)- or (3R,4R)-1-benzyl-4-(halogen-aryl)-pyrrolidine-3-carboxylic acids of formula I or salts thereof, wherein X and Y are each independently hydrogen or a halogen atom, with the proviso that at least one of X or Y is a halogen atom. The compounds of formula I are useful as starting materials or intermediates for the preparation of pharmaceutically active compounds, especially for compounds, which are useful for the treatment of central nervous system disorders.

Abstract: The invention relates to a novel process for the preparation of Ruthenium metathesis catalysts of the formula Ruthenium metathesis catalysts have been widely applied in the synthesis of macrocyclic drug compounds.

Abstract: The invention relates to novel metathesis catalysts of the formula a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula VII which have the potential to be useful as HCV protease inhibitors.

Abstract: The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.

Abstract: The invention relates to a novel process for the preparation of Ruthenium metathesis catalysts of the formula Ruthenium metathesis catalysts have been widely applied in the synthesis of macrocyclic drug compounds.

Abstract: The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.

Abstract: Disclosed are novel metathesis catalysts of the formula wherein R1, R2, R3, R4, R5, R6, X1, X2, L and Y are as described herein, a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.

Abstract: The invention relates to a novel process for the preparation of (3S,4S)- or (3R,4R)-1-benzyl-4-(halogen-aryl)-pyrrolidine-3-carboxylic acids of formula I or salts thereof, wherein X and Y are each independently hydrogen or a halogen atom, with the proviso that at least one of X or Y is a halogen atom. The compounds of formula I are useful as starting materials or intermediates for the preparation of pharmaceutically active compounds, especially for compounds, which are useful for the treatment of central nervous system disorders.

Abstract: The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3?, —CO—NR8R8?, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4? and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4? and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8?; and R8 and R8? are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of su

Abstract: The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3?, —CO—NR8R8?, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4? and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4? and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8?; and R8 and R8? are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of suc

Abstract: The invention relates to novel metathesis catalysts of the formula a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula VII which have the potential to be useful as HCV protease inhibitors.

Abstract: The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.

Abstract: The invention relates to the preparation of enantiomerically pure (S)-1,1,1-trifluoro-2-propanol by asymmetric hydrogenation of 1,1,1-trifluoroacetone which process comprises hydrogenating 1,1,1-trifluoroacetone in the presence of a ruthenium phosphine complex catalyst represented by formula Ru(E)(E?)(L)(A) wherein E, E? are both chloro or E is hydrogen and E? is BH4; L is a chiral diphosphine ligand; and A is an optionally chiral diamine wherein hydrogenation occurs in the presence of a weak base, with or without an additive, when E and E? are both chloro or b) in the absence of a base and an additive when E and E? are hydrogen and BH4.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula I comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula I and the corresponding salts and/or esters are pharmaceutically active substances.

Abstract: The invention relates to the preparation of enantiomerically pure (S)-1,1,1-trifluoro-2-propanol by asymmetric hydrogenation of 1,1,1-trifluoroacetone which process comprises hydrogenating 1,1,1-trifluoroacetone in the presence of a ruthenium phosphine complex catalyst represented by formula Ru(E)(E)(L)(A) wherein E, E? are both chloro or E is hydrogen and E? is BH4; L is a chiral diphosphine ligand; and A is an optionally chiral diamine wherein hydrogenation occurs in the presence of a weak base, with or without an additive, when E and E? are both chloro or b) in the absence of a base and an additive when E and E? are hydrogen and BH4.

Abstract: Disclosed are novel metathesis catalysts of the formula wherein R1, R2, R3, R4, R5, R6, X1, X2, L and Y are as described herein, a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula I comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula I and the corresponding salts and/or esters are pharmaceutically active substances.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula I comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula I and the corresponding salts and/or esters are pharmaceutically active substances.

Abstract: The invention comprises a novel process for the preparation of an epothilone derivative of formula I: wherein R1 and R2 independently from each other represent hydrogen or protecting groups and R3 is methyl or trifluoromethyl, which are useful precursors in the synthesis of the desoxyepothilone derivatives of the formula IV: wherein R3 is methyl or trifluoromethyl. The desoxepothilones of formula IV inhibit the growth of tumor cells and are therefore promising candidates for novel anticancer agents.